Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000904454-26-000591·Contineum Therapeutics, Inc.
Schedule 13G ownership disclosure
Contineum Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 21217B100
Event date: 2026-11-03
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Johnson & Johnson Innovation - JJDC, Inc.
Shares: 1,979,173.00 · Class: 5.6%
- JOHNSON & JOHNSON
Shares: 1,979,173.00 · Class: 5.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000904454-26-000591
- Form type
- SCHEDULE 13G/A
- Filer
- Contineum Therapeutics, Inc.
- CIK
- CIK 1855175
- Filed
- Nov 06, 2026
- Reporting period
- Nov 03, 2026
- Description
- Schedule 13G beneficial ownership